DrugPatentWatch Database Preview
Details for Patent: 6,899,699
» See Plans and Pricing
Which drugs does patent 6,899,699 protect, and when does it expire?
Patent 6,899,699 protects OZEMPIC and SAXENDA and is included in two NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirteen patent family members in nine countries.
Summary for Patent: 6,899,699
| Title: | Automatic injection device with reset feature |
| Abstract: | The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all. |
| Inventor(s): | Enggaard; Christian (Hiller.o slashed.d, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 10/038,781 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,899,699 |
|
Patent Claim Types: see list of patent claims | Device; Use; |
Drugs Protected by US Patent 6,899,699
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,899,699
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2001 00018 | Jan 05, 2001 |
International Family Members for US Patent 6,899,699
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 296650 | Start Trial | |||
| China | 1313168 | Start Trial | |||
| China | 1509193 | Start Trial | |||
| Germany | 60204422 | Start Trial | |||
| Denmark | 1351732 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
